Compare OCFC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | XNCR |
|---|---|---|
| Founded | 1902 | 1997 |
| Country | United States | United States |
| Employees | 1007 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 881.9M |
| IPO Year | N/A | 2013 |
| Metric | OCFC | XNCR |
|---|---|---|
| Price | $18.85 | $12.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $21.33 | ★ $22.33 |
| AVG Volume (30 Days) | 556.3K | ★ 735.9K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $47.51 | N/A |
| Revenue Next Year | $21.97 | $4.80 |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $15.85 | $6.92 |
| 52 Week High | $20.61 | $18.69 |
| Indicator | OCFC | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 56.12 |
| Support Level | $17.29 | $12.29 |
| Resistance Level | $19.33 | $12.87 |
| Average True Range (ATR) | 0.42 | 0.65 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 60.75 | 61.62 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.